The global peptide therapeutics market is valued at US$ 38.0 Billion for 2023 and is expected to reach US$ 106.0 Billion by 2033, expanding at an impressive CAGR of 10.8% over the period of 2023 to 2033.
Peptide therapeutics currently account for a 53.7% share of the global drug discovery market, with the Asia Pacific market advancing rapidly in peptide-based drugs. For more than a century, peptide medicines have been used to treat metabolic illnesses. In comparison to tiny chemical compounds, peptide drugs offer numerous advantages, resulting in huge demand across geographies.
| Attributes | Details |
|---|---|
| Market CAGR for Peptide Therapeutics (2023 to 2033) | 10.8% |
| Market Size for Peptide Therapeutics (2023) | US$ 38.0 Billion |
| Market Size for Peptide Therapeutics (2033) | US$ 106.0 Billion |
| Global Market Absolute Dollar Growth (US$ Million/Billion) | US$ 68.0 Billion |
The comparative analysis and market growth rate of the global market for peptide therapeutics, as studied by Future Market Insights, Inc may show a negative BPS growth in the H1-2023 outlook as compared to H1-2023 projected period by 20 BPS, and a negative BPS dip is expected in H1-2023 over H1- 2021 duration with 56 Basis Point Share (BPS).
The dip in the BPS values observed is due to the high-cost factors associated with manufacturing a peptide, as well as the limitation of the molecule having a short half-life, therefore incurring high research expenditures. However, with a wide range of targets available for peptides, manufacturers have opportunities to develop novel peptide therapeutic formulations, thus impacting the overall market positively.
The market is subject to changes in lieu of factors such as research funding and grants and outsourcing of manufacturing capabilities in accordance with the macro and industry standards. Conversely, advancements in next-generation therapeutics and peptide-based targeted drug delivery for cancer cells may aid in the positive growth traction of the overall market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The peptide therapeutics market expanded at a CAGR of 10% from 2014 to 2021.
Peptide therapeutic companies have come to appreciate the role that peptide pharmaceuticals can play in addressing unmet medical needs and how this class of compounds can be an excellent complement or even a preferable alternative to small molecule and biological therapeutics, resulting in a revival of interest and scientific momentum in peptide drug discovery over the last decade.
The market is being driven by the rising prevalence of cancer and metabolic disorders, increased investments in the research & development of innovative medications, and technological developments in peptide therapies.
Peptide pharmaceuticals have developed a wide range of applications in medicine and biotechnology during the last decade, and therapeutic peptide research is undergoing a revival for commercial reasons. Peptide drug discovery has a significant role in the healthcare sector. LupronTM, a peptide medication from Abbott Laboratories, is used to treat prostate cancer and other conditions.
Chronic diseases such as cancer, cardiovascular disease, and diabetes are the major causes of death and disability worldwide, according to the World Health Organization (WHO). As a result, the rising prevalence of chronic diseases is driving demand for effective medicines, which is likely to propel the peptide therapeutics market forward.
Peptide therapeutics demand is predicted to surge at a CAGR of 10.8% from 2023 to 2033, with the global market expected to close in on a valuation of US$ 106 Billion by 2033.
Oral Peptide-based Drugs Becoming a Hit
Due to a decrease in non-peptide chemical medications accessible in the market, sales of peptide therapeutic companies are currently rising. The peptides generics market is expected to develop as the patent cliff rises.
Because pharma businesses are shifting their focus to better potential in the peptide therapies sector, CMOs that provide end-to-end services to biotech and pharmaceutical companies are rising.
As peptides are a common component of food, both the stomach and intestines contain a plethora of enzymes that can break them down, and most peptide-based drugs do not survive the gastrointestinal tract.
Heinis's Group is currently using a novel technology to develop oral peptide drugs that act directly on gastrointestinal targets, bypassing the bloodstream. Oral peptide drugs may play a crucial role in the treatment of a wide range of disorders.
Increasing Use of Peptides in Cancer & Diabetes Treatment
Peptides were originally used solely for diagnostics and hormone therapy; however, with technological advancements, they are now widely used for the treatment of cancer and chronic metabolic illnesses as well.
Chemotherapy, which is the most common kind of cancer treatment, is beset by problems due to its inability to deliver the right amount of medicine to the right place at the right time. It also affects the body's natural cells. The use of peptide-based therapeutics in cancer treatment has opened up a promising new channel for the peptide therapeutics market's future growth.
Apart from that, peptide therapies are widely utilized in injections for diabetic patients, thanks to the emergence of novel synthetic techniques that reduce injection frequency while also improving stability and other physical features.
This is influencing the usage of peptide therapies over oral drugs, which coincides with the rising incidence of diabetes and the growing preference for rapid and accurate treatment techniques.
Rising Popularity of Peptide-based Therapeutics in Cosmeceuticals
Peptides are also employed in cosmeceutical operations to slow down the aging process of the skin. This, combined with people's growing awareness of their physical appearance and a desire to keep their skin looking young and healthy, is fuelling global acceptance of cosmetic operations and peptide-based therapeutics.
Furthermore, the need for multifunctional peptide-based drug materials is being fuelled by the growing trend of tailored and targeted treatments. This, together with increased investments in the development of new peptide therapies for the treatment of autoimmune and inflammatory illnesses, is expected to boost market growth.
Principal Consultant
Peptide Therapeutics Market:
| Attributes | Peptide Therapeutics Market |
|---|---|
| CAGR (2023 to 2033) | 10.8% |
| Market Value (2023) | US$ 38.0 Billion |
| Growth Factor | As a result of a number of factors, including a growth in the older population and the incidence of chronic diseases, the market for peptide therapies is predicted to expand. |
| Opportunity | The increase in product development and technological advancements is a significant market trend that is projected to boost expansion. |
| Key Trends | An increase in patient knowledge of peptide therapy developments. |
Peptide Drug Conjugates Market:
| Attributes | Peptide Drug Conjugates Market |
|---|---|
| CAGR (2023 to 2033) | 18.58% |
| Market Value (2023) | US$ 838.43 Million |
| Growth Factor | The robust clinical trial pipeline for peptide drug conjugates increased R&D investments for developing PDCs, and the rising illness burden contribute to market expansion. |
| Opportunity | The new PDC approval for the treatment of numerous forms of cancer may increase market growth in the near future. |
| Key Trends | The strong product pipeline and increasing financial investments in research & development provide a profitable market growth opportunity. |
Peptide Synthesis Market:
| Attributes | Peptide Synthesis Market |
|---|---|
| CAGR (2023 to 2033) | 13% |
| Market Value (2023) | US$ 700.11 Million |
| Growth Factor | Inorganic strategies for peptide synthesis, such as collaborations between industry competitors, are projected to drive growth in the global peptide synthesis market. |
| Opportunity | Major players are focusing on inorganic tactics such as collaborations to expand their businesses, which are projected to promote market growth. |
| Key Trends | The rising number of cancer cases is likely to drive market expansion. |
| Attributes | Details |
|---|---|
| Top Route Of Administration | Parenteral Route |
| CAGR % 2017 to 2022 | 10.3% |
| CAGR % 2023 to End of Forecast(2033) | 10.8% |
Parenteral Route Highly Preferred for Peptide Drug Delivery
The parenteral route provides improved bioavailability, faster onset of action, and superior clinical results, making it the preferred option for peptide therapeutic drug delivery. The highest market share for peptide therapeutics, 70.7%, is accounted for by the parenteral route of administration of peptide medicines.
Currently, the majority of peptide medications are delivered via the parenteral route. Alternative administration modes, including oral, intranasal, and transdermal delivery routes, are gaining momentum as technology advances.
The parenteral method, on the other hand, has the potential for side effects and necessitates the use of specialized personnel for delivery. As a result, market participants are turning to alternative administration methods, such as the oral route, which causes less pain and eliminates the need for outside assistance.
Adoption of various delivery forms could also allow peptide medicines to be used more widely in other disease areas, such as inflammation, where topical peptide administration could be the foundation for extremely effective new treatments.
| Attributes | Details |
|---|---|
| Top Application Type | Cancer |
| CAGR % 2017 to 2022 | 10.2% |
| CAGR % 2023 to End of Forecast (2033) | 10.6% |
A Rise in Patients with Cancer and Other Chronic Conditions May Promote the Cancer Segment.
The cancer category led the global market in 20213 in terms of application. The top cause of death in the world is cancer. The World Health Organization estimates that cancer may be responsible for roughly 10 million deaths worldwide in 2020.
Chemotherapy, the main form of cancer treatment, faces significant difficulties because it can't administer the right dosage of medication directly, severely affecting the body's normal cells.
As therapeutic peptides may deliver drugs with precise binding sites, their use in the treatment of cancer has created a viable channel for the future expansion of the global peptide therapeutics market.
Over the last few years, peptide-based therapeutic vaccines have gained recognition as one of the most successful treatments for tumor immunotherapy. Due to the growth in the geriatric population, the prevalence and incidence rate of other chronic problems such as Alzheimer's, diabetes, heart diseases, and immunological disorders are expected to drive the global peptide and Alzheimer's peptide therapies markets in the coming years.
High Government Investments in R&D of Peptide Medications Fuelling Market Growth in North America
The global market for peptide therapeutics has been studied across North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
Throughout the projected period, North America is expected to lead the global market. This regional market is prominent as a result of factors such as increased awareness of peptide treatments. The growing need for diagnostics in cancer and other diseases and the expanding biotechnology industry.
Increased government and industry spending on research and development is also predicted to help peptide therapies maintain their dominance over the coming years. In this region, a well-established biopharmaceutical and pharmaceutical industry is a primary driver for market growth.
The peptide therapeutics markets in Western Europe and Eastern Europe are expected to be driven by the rising popularity of peptide therapeutics treatment procedures, increasing medical research & development, etc.
The Latin American market for peptide therapeutics is expected to account for steady market growth.
The Asia Pacific market for peptide therapeutics is predicted to expand at a high CAGR throughout the forecast period, making it a highly viable market. This is due to a large patient pool, rising healthcare expenditure, and an increasing need for innovative and advanced therapies.
The MEA market for peptide therapeutics is expected to progress at a slightly slower rate than other regions but is expected to pick up pace towards the end of the projection period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Country | United States |
|---|---|
| HCAGR (2017 to 2022) | 10.5% |
| CAGR (2023 to 2033) | 11% |
| Country | United Kingdom |
|---|---|
| HCAGR (2017 to 2022) | 9.3% |
| CAGR (2023 to 2033) | 9.8% |
| Country | Germany |
|---|---|
| HCAGR (2017 to 2022) | 94% |
| CAGR (2023 to 2033) | 9.9% |
| Country | China |
|---|---|
| HCAGR (2017 to 2022) | 10.6% |
| CAGR (2023 to 2033) | 11.1% |
| Country | India |
|---|---|
| HCAGR (2017 to 2022) | 11.3% |
| CAGR (2023 to 2033) | 11.7% |
| Attributes | Details |
|---|---|
| United States Market Size (US$Million/Billion) by End of Forecast Period(2033) | US$ 41.1 Billion |
| United States Market Absolute Dollar Growth (US$ Million/Billion) | US$ 26.7 Billion |
High Incidence of Cancer Driving Demand for Peptide-based Therapeutics
According to the American Cancer Society's forecasts, a little more than 1.9 Million new cancer cases are predicted to be diagnosed in the United States in 2022. Cancer is the 2nd leading cause of death in the United States, trailing only heart disease.
This data suggests that peptides may become more relevant in the United States healthcare industry and that peptides may progress through clinical trials. Demand for peptide therapies is predicted to rise as cancer becomes more prevalent.
Due to factors such as an increase in the number of research programs in the medical business as well as an increase in the number of diseases in the country, the United States has the biggest market share.
| Attributes | Details |
|---|---|
| United Kingdom Market Size (US$Million/Billion) by End of Forecast Period(2033) | US$ 3.4 Billion |
| United Kingdom Market Absolute Dollar Growth (US$ Million/Billion) | US$ 2.1 Billion |
Throughout the anticipated period, the United Kingdom market for peptide therapeutics is expected to expand at a strong CAGR of 9.8%. Earlier, from 2017 to 2022, the market in the United Kingdom grew at a solid CAGR of 9.8%.
The expansion of the peptide therapeutics market in the United Kingdom is anticipated to be aided by rising awareness of the applications of peptides for the treatment of various chronic disorders. The United Kingdom peptide therapeutics markets are anticipated to be driven by factors such as the growing demand for peptide therapeutics treatments, increased medical research, and development, etc.
| Attributes | Details |
|---|---|
| Germany Market Size (US$Million/Billion) by End of Forecast Period(2033) | US$ 5.7 Billion |
| Germany Market Absolute Dollar Growth (US$ Million/Billion) | US$ 3.5 Billion |
The German market is estimated to grow at a solid CAGR of 9.9% over the forecast period. Prior to that, the German market expanded at a respectable HCAGR of 9.4% from 2017 to 2022.
The expansion of the peptide therapeutics market in the region is being aided by the region's well-developed healthcare infrastructure, expensive peptide therapeutics medications, and advantageous reimbursement regulations. The generic market is expected to increase rapidly in the near future as a result of decreasing raw material costs and the patent expiration of popular medications.
| Attributes | Details |
|---|---|
| India Market Size (US$ Million/Billion) by End of Forecast Period(2033) | US$ 1.7 Billion |
| India Market Absolute Dollar Growth (US$ Million/Billion) | US$ 1.1 Billion |
The Indian peptide therapeutics market is predicted to grow at a healthy rate over the coming years. Increased frequency of chronic diseases, increasing aging population, and rising healthcare costs are all contributing to market expansion in the country.
In terms of the number of cancer cases, India is ranked third among all nations. According to the National Cancer Registry Programme report, over 1,300,000 people in India are diagnosed with cancer each year. This surge is attributed to unhealthy lifestyles, increased urban pollution, cigarette and alcohol consumption, and a rise in obesity.
According to the Indian Council of Medical Research (ICMR), cancer cases in India may climb 12% in the next five years. Breast cancer, cervical cancer, and oral cancer are the most common types of cancer among Indians.
Synthetic peptide drugs can be made to look like naturally occurring peptides and can be used to treat cancer and other serious illnesses. Hemmo has been supplying peptide products and custom peptide synthesis for more than 38 years, making it one of India's major makers of synthetic peptide drugs provider.
Leading market players are huge and well-established, with a high level of brand loyalty. Major peptide therapeutics medication manufacturers in India are Emcure Pharmaceutical Pvt. Ltd., Cipla Ltd., Gland Pharma Limited, Troikaa Pharmaceuticals Ltd., and Biological E Limited (IN).
| Attributes | Details |
|---|---|
| China Market Size (US$ Million/Billion) by End of Forecast Period(2033) | US$ 4.7 Billion |
| China Market Absolute Dollar Growth (US$ Million/Billion) | US$ 3.1 Billion |
Due to an increase in the number of elderly people, the expansion of healthcare infrastructure, and an increase in investment projects in the region, China is expected to experience significant growth. Due to the rising frequency of infectious diseases in the region, the market in China is predicted to expand at a rapid CAGR of 11.1% over the course of the projected period.
The market in China is being driven by an increase in the number of elderly people and a rise in healthcare spending. The China peptide therapeutics market is also expected to benefit from a huge patient base and strong demand for more advanced treatments.
There are several significant participants in the moderately competitive peptide therapies industry. For the international expansion of their product portfolios, the leading players are engaged in strategic alliances such as acquisitions and collaborations, coupled with research efforts.
Leading suppliers of peptide therapeutics are concentrating on market expansion through distribution contracts, joint ventures, and white space investigation. Additionally, established businesses are collaborating with regional firms to improve their area presence and boost their manufacturing capabilities.
Recent Development:
| Date | December 2020 |
|---|---|
| Company | ONL Therapeutics, Inc. |
| Details | In a Series B financing round that was held in December 2020, ONL Therapeutics, Inc., a biopharmaceutical business with headquarters in Michigan that creates innovative medicines, secured US$ 46.9 Million. With the help of this grant, peptide manufacturing would be developed in order to get ready for an IND filing for phase 2 research. |
| Date | June 2022 |
|---|---|
| Company | Ariceum Therapeutics |
| Details | Ariceum Therapeutics, a private biotech company creating a radiopharmaceutical product, received US$25 million in a second round of funding from EQT Life Sciences in June 2022. Ariceum's lead asset and proprietary peptide derivative, satoreotide, would be developed thanks to the funding. |
| Date | May 2022 |
|---|---|
| Company | Biohaven Pharmaceutical Holding Company Ltd. |
| Details | The developer of NURTEC ODT, an advanced dual-acting migraine medicine approved for both acute treatments and episodic migraine prevention in adults, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced a new collaboration in May 2022. |
| Date | February 2022 |
|---|---|
| Company | Amgen |
| Details | Amgen and Plexium, Inc. announced a multi-year research collaboration and license agreement in February 2022 to develop new targeted protein degradation treatments for hitherto difficult pharmacological targets. By using Amgen's experience in generating multispecific compounds, the multiyear collaboration may aid in the development of new molecular glue therapies. |
| Date | May 2022 |
|---|---|
| Company | Bristol Myers Squibb |
| Details | Bristol Myers Squibb and LOTTE Corporation announced in MAY 2022 that LOTTE had made the decision to purchase Bristol Myers Squibb's production facility in East Syracuse, New York. The US operations of LOTTE's new biologics CDMO may be located in East Syracuse. |
| Date | May 2021 |
|---|---|
| Company | ISSAR Pharmaceuticals |
| Details | ISSAR Pharmaceuticals planned in May 2021 to license out its peptide-based unique chemical entities with a pre-IND file and a United States Patent for various neglected healthcare demands of the people, seeking to make it accessible and inexpensive for improved outcomes. |
High incidence of cancer-driving demand witnessed higher growth.
The market is estimated to secure a valuation of US$ 38 billion in 2023.
The market is forecast to register a CAGR of 10.8% through 2033.
The cancer category led the global market in terms of application.
An increase in patient knowledge is a prominent trend in the market.
1. Executive Summary | Peptide Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ million) Analysis, 2017 to 2022 4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Application Type, 2017 to 2022 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Application Type, 2023 to 2033 5.3.1. Cancer 5.3.2. Cardiovascular 5.3.3. Central Nervous Systems 5.3.4. Metabolic Disorders 5.3.5. Infection 5.3.6. Hematological Disorders 5.3.7. Gastrointestinal Disorders 5.3.8. Dermatology 5.3.9. Respiratory Disorders 5.3.10. Acromegaly 5.3.11. Other Application Types 5.4. Y-o-Y Growth Trend Analysis By Application Type, 2017 to 2022 5.5. Absolute $ Opportunity Analysis By Application Type, 2023 to 2033 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route Of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Route Of Administration, 2017 to 2022 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Route Of Administration, 2023 to 2033 6.3.1. Parenteral Route 6.3.2. Mucosal Route 6.3.3. Oral Route 6.3.4. Transdermal Route 6.4. Y-o-Y Growth Trend Analysis By Route Of Administration, 2017 to 2022 6.5. Absolute $ Opportunity Analysis By Route Of Administration, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By Drug Type, 2017 to 2022 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Type, 2023 to 2033 7.3.1. Branded 7.3.2. Generic 7.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017 to 2022 7.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) Analysis By Region, 2017 to 2022 8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. Asia Pacific excluding Japan (APEJ) 8.3.6. Japan 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Application Type 9.2.3. By Route Of Administration 9.2.4. By Drug Type 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Application Type 9.3.3. By Route Of Administration 9.3.4. By Drug Type 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Application Type 10.2.3. By Route Of Administration 10.2.4. By Drug Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Application Type 10.3.3. By Route Of Administration 10.3.4. By Drug Type 10.4. Key Takeaways 11. Western Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. USA 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Nordic countries 11.2.1.7. BENELUX 11.2.1.8. Rest Of Western Europe 11.2.2. By Application Type 11.2.3. By Route Of Administration 11.2.4. By Drug Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Application Type 11.3.3. By Route Of Administration 11.3.4. By Drug Type 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Russia 12.2.1.2. Poland 12.2.1.3. Rest Of Eastern Europe 12.2.2. By Application Type 12.2.3. By Route Of Administration 12.2.4. By Drug Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Application Type 12.3.3. By Route Of Administration 12.3.4. By Drug Type 12.4. Key Takeaways 13. APEJ Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. India 13.2.1.3. ASEAN 13.2.1.4. Australia & New Zealand 13.2.2. By Application Type 13.2.3. By Route Of Administration 13.2.4. By Drug Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Application Type 13.3.3. By Route Of Administration 13.3.4. By Drug Type 13.4. Key Takeaways 14. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.2. By Application Type 14.2.3. By Route Of Administration 14.2.4. By Drug Type 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Application Type 14.3.3. By Route Of Administration 14.3.4. By Drug Type 14.4. Key Takeaways 15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2022 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest Of MEA 15.2.2. By Application Type 15.2.3. By Route Of Administration 15.2.4. By Drug Type 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Application Type 15.3.3. By Route Of Administration 15.3.4. By Drug Type 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Application Type 16.1.2.2. By Route Of Administration 16.1.2.3. By Drug Type 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Application Type 16.2.2.2. By Route Of Administration 16.2.2.3. By Drug Type 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Application Type 16.3.2.2. By Route Of Administration 16.3.2.3. By Drug Type 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Application Type 16.4.2.2. By Route Of Administration 16.4.2.3. By Drug Type 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Application Type 16.5.2.2. By Route Of Administration 16.5.2.3. By Drug Type 16.6. USA 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Application Type 16.6.2.2. By Route Of Administration 16.6.2.3. By Drug Type 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Application Type 16.7.2.2. By Route Of Administration 16.7.2.3. By Drug Type 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Application Type 16.8.2.2. By Route Of Administration 16.8.2.3. By Drug Type 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Application Type 16.9.2.2. By Route Of Administration 16.9.2.3. By Drug Type 16.10. Nordic countries 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Application Type 16.10.2.2. By Route Of Administration 16.10.2.3. By Drug Type 16.11. BENELUX 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Application Type 16.11.2.2. By Route Of Administration 16.11.2.3. By Drug Type 16.12. Russia 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Application Type 16.12.2.2. By Route Of Administration 16.12.2.3. By Drug Type 16.13. Poland 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Application Type 16.13.2.2. By Route Of Administration 16.13.2.3. By Drug Type 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Application Type 16.14.2.2. By Route Of Administration 16.14.2.3. By Drug Type 16.15. India 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Application Type 16.15.2.2. By Route Of Administration 16.15.2.3. By Drug Type 16.16. ASEAN 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Application Type 16.16.2.2. By Route Of Administration 16.16.2.3. By Drug Type 16.17. Australia & New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Application Type 16.17.2.2. By Route Of Administration 16.17.2.3. By Drug Type 16.18. Japan 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Application Type 16.18.2.2. By Route Of Administration 16.18.2.3. By Drug Type 16.19. GCC countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Application Type 16.19.2.2. By Route Of Administration 16.19.2.3. By Drug Type 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Application Type 16.20.2.2. By Route Of Administration 16.20.2.3. By Drug Type 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Application Type 16.21.2.2. By Route Of Administration 16.21.2.3. By Drug Type 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Application Type 17.3.3. By Route Of Administration 17.3.4. By Drug Type 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Eli Lilly and Company 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. AstraZeneca plc 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Merck & Co. Inc 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Ipsen S.A 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Novo Nordisk A/S 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Teva Pharmaceutical Industries Ltd. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Amgen, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Bachem Holding AG 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Novartis AG 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Pfizer, Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Peptide Therapeutics Market
